| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
Correspondence to: Gregory W. Albers, MD, Stanford Stroke Center, Building B, Suite 325, 701 Welch Rd, Palo Alto, CA 94304-1705; e-mail: albers{at}leland.stanford.edu
 |
Introduction |
|---|
 TOP Introduction 1. acute ischemic stroke...2. stroke prevention 3. cerebral venous sinus...RecommendationsReferences |
|---|
|
|
|
|
1. ACUTE ISCHEMIC STROKE |
|---|
|
TOPIntroduction1. acute ischemic stroke...2. stroke prevention 3. cerebral venous sinus...RecommendationsReferences |
|---|
Background: The rationale for thrombolytic therapy is based on the recognition that most ischemic strokes are caused by thrombotic or thromboembolic arterial occlusions.10 11 Pathologic and angiographic studies demonstrate the presence of occlusive clot in up to 80% of ischemic strokes.10 12 Neuronal death and brain infarction evolve in a time-dependent fashion determined by both the duration and severity of the ischemic insult.13 14 Therapeutic strategies designed to restore cerebral perfusion in a timely fashion have the potential to limit the cellular, biochemical, and metabolic consequences of cerebral ischemia that ultimately lead to irreversible brain injury. Considerable experimental evidence using thrombolytic agents in animal stroke models shows that autologous clots can be effectively lysed by thrombolytics without excessive risk of brain hemorrhage, and functional neurologic recovery has been demonstrated.14 15 16 17 Coexistent hypertension may be a major factor influencing the risk of brain hemorrhage associated with thrombolytic therapy.18 19 The concomitant use of other antithrombotic agents, such as the combination of streptokinase and aspirin, increasesthe risk of hemorrhagic transformation in experimental models.20 21
Early Studies: Early human trials of thrombolytic therapy for ischemic stroke conducted in the pre-CT era were abandoned because of safety concerns. Available imaging technologies did not permit the exclusion of patients with intracerebral hemorrhage, tumor, or other nonischemic diagnoses, and treatment was often given days or even weeks after symptom onset.22 23
Interest in thrombolytic therapy for acute ischemic stroke was rekindled due to the success of potent thrombolytic agents in the management of acute myocardial infarction (MI), a better understanding of the dynamic nature of cerebral ischemia, and the ready availability of CT imaging.24 25 26 A meta-analysis of thrombolytic stroke studies reported by Wardlow and Warlow27 in 1992 was encouraging and suggested that further clinical trials should be conducted in large numbers of patients.
Preliminary feasibility and safety trials in stroke patients ensued. von Kummer et al28 reported three cerebral hematomas and seven hemorrhagic transformations in 33 patients treated with tPA and heparin. Wolpert et al29 reported an 11% incidence of parenchymal hematoma in an open study of 104 patients given IV tPA within 8 h of stroke onset. Hemorrhagic transformation was more common in patients who had hypertension, were treated beyond 6 h after stroke onset, or received large doses of tPA. Studies also evaluated therapeutic efficacy based on the success of arterial recanalization. A Japanese randomized trial30 of 98 patients reported recanalization in 25.6% of the tPA-treated patients compared with a spontaneous recanalization rate of only 4.3% in placebo-treated patients. del Zoppo et al11 reported a 1-h recanalization rate of 34.4% in an angiographic study of 93 patients treated with tPA. Recanalization rates varied with the site of occlusion, ranging from only 8% with extracranial occlusions of the internal carotid artery, to 26% and 38% with middle cerebral artery (MCA) stem and distal branch occlusions, respectively.
Pilot studies31 32 designed to define the safety and optimal dose of tPA for future large-scale trials were completed using 90-min and 180-min therapeutic windows. Based on these results, a dose of 0.9 mg/kg was selected for future large-scale trials.
Large-Scale Trials of tPA: IV tPA has been evaluated in four large-scale trials using different doses, therapeutic windows, and treatment protocols: the NINDS recombinant t-PA study,1 33 34 the European Cooperative Acute Stroke Study (ECASS)-I ,2 the ECASS-II,3 and the ATLANTIS rt-PA (Alteplase) Acute Stroke Trial (parts A and B).7 7a
The NINDS rtPA Acute Stroke Study Group1 conducted a randomized, double-blind, placebo-controlled study and enrolled 624 patients to receive treatment within 3 h of clearly defined symptom onset. A pretreatment CT scan was required to exclude the presence of intracerebral hemorrhage, along with a set of strict inclusion and exclusion criteria (see "Recommendations"). Eligible patients received IV tPA, 0.9 mg/kg (maximum of 90 mg), or placebo treatment. The tPA was given as a 10% bolus over 1 min, and the remainder of the total dose was infused over 60 min. In order to reduce the risk of intracerebral hemorrhage associated with hypertension, strict treatment algorithms were developed to monitor and maintain BP of < 185 mm Hg systolic and 110 mm Hg diastolic. Patients who required aggressive measures to attain pretreatment BP below these limits were not enrolled.
In part 1 of the NINDS study,1 291 patients were enrolled to assess early neurologic recovery. Early treatment response was measured using the National Institutes of Health Stroke Scale (NIHSS) 24 h after enrollment, and an improvement of four or more points or a complete resolution of the neurologic deficit was considered a positive response. In part 2 of the NINDS study,1 333 patients were enrolled and the primary outcome measure was the percentage of patients with minimal or no disability at 3 months, as measured using a global test statistic of four stroke scales (NIHSS, Barthel Index [BI], modified Rankin Scale [mRS], Glasgow Outcome Scale [GOS]) and by each scale individually.
Combined data from parts 1 and 2 were reported because the results of part 1 were unknown before part 2 was completed. In part 1, there was no significant difference in the percentages of patients with neurologic improvement at 24 h using the criteria defined above. However, a secondary analysis showed a statistically significant improvement in the median NIHSS score at 24 h in the tPA group (8 vs 12; p < 0.02) and a significant benefit in all four outcome measures at 3 months. In part 2, the global odds ratio (OR) for favorable outcome with tPA was 1.7 (confidence interval [CI], 1.2 to 2.6). Patients treated with tPA were at least 30% more likely to have minimal or no disability at 3 months compared with placebo-treated patients. Treatment with tPA resulted in an 11 to 13% absolute increase in the number of patients with excellent outcomes, and additional reductions were observed in the proportion of patients severely disabled or dead at 3 months. A similar degree of benefit was seen for all stroke subtypes. The mortality rate at 3 months was 17% in the tPA-treated group and 21% in the placebo-treated group (p = 0.30). Symptomatic intracerebral hemorrhage occurred in 6.4% of patients receiving tPA vs 0.6% of the placebo-treated patients (p < 0.001).
The benefits of tPA were consistent regardless of patient age, stroke subtype, stroke severity, or prior use of aspirin. While patients with severe neurologic deficits at baseline were less likely to have a good outcome regardless of treatment, a subgroup analysis of patients > 75 years old with an initial NIHSS of > 20 demonstrated a reduction in death or severe disability with tPA compared with placebo.33
Two variables were associated with an increased risk of intracerebral hemorrhage in patients treated with tPA: the severity of neurologic deficit as measured on the NIHSS score (OR, 1.8; 95% CI, 1.2 to 2.9), and brain edema or mass effect on the pretreatment CT scan (OR, 7.8; 95% CI, 2.2 to 27.1).1 Despite the increased risk of hemorrhage, patients with severe strokes were more likely to have favorable outcomes if treated with tPA (adjusted OR, 4.3; 95% CI, 1.6 to 11.9). Patients with edema or with mass effect on CT were also more likely to have a favorable outcome with tPA (adjusted OR, 3.4; 95% CI, 0.6 to 20.7), although this difference was not statistically significant. The benefits realized at 3 months with tPA therapy were achieved without early excess in morbidity and mortality due to intracerebral bleeding.
The benefits of tPA demonstrated in the NINDS study are durable and sustained during long-term follow-up.35 At 12 months, the global statistic favored the tPA-treated group (OR for a favorable outcome, 1.7; 95% CI, 1.2 to 2.3) and the tPA-treated patients were at least 30% more likely to have minimal or no disability than the placebo-treated patients. The difference favoring tPA in absolute terms ranged from 11 to 13%, depending on the outcome variable, essentially the same at 1 year as at 3 months. There was no significant difference in mortality at 12 months (24% in the tPA group vs 28% in the placebo group).
The ECASS-I trial2 was a multicenter, double-blind, placebo-controlled trial that randomized 620 patients within 6 h of stroke onset to treatment with IV tPA at a dose of 1.1 mg/kg (maximum of 100 mg) or placebo. Primary end points included the BI and mRS at 90 days. Patients with major early infarct signs affecting > 33% of the MCA territory were to be excluded, as were patients with clinically very severe strokes. An intention-to-treat analysis and a target population analysis were planned a priori in the protocol. The target population analysis included only 511 patients because 109 patients were eliminated due to major protocol violations, most commonly involving violation of the CT exclusion criteria for early infarct signs.
There was no significant difference in the BI at 3 months in either the intention-to-treat or target populations (patients without protocol violations). In the target population analysis, there was a significant difference of one point in the mRS favoring treatment with tPA (p = 0.035). In the target population, 41% of tPA-treated patients were asymptomatic or had minimal disability compared with 29% in the placebo group (mRS, 0 or 1; p < 0.05). Other predefined secondary end points, including the combined BI and mRS, speed of neurologic recovery, and length of hospital stay, favored tPA-treated patients.
There were no statistically significant differences in the 30-day mortality rates or in the overall incidence of intracerebral hemorrhages. However, the incidence of major parenchymal hemorrhages was 19.8% in the tPA group vs 6.5% in the control group (p < 0.001). A post hoc exploratory analysis of the ECASS data showed that the severity of the initial clinical deficit (OR, 2.5; 95% CI, 1.6 to 4.0) and the presence of early major ischemic changes (hypoattenuation exceeding one third of the MCA territory or diffuse swelling of the entire hemisphere) on CT scan (OR, 3.5; 95% CI, 2.3 to 5.3) were associated with increased risk of hemorrhagic infarction. The ECASS investigators concluded that tPA might be effective when given within 6 h of stroke onset, provided there are no major signs of infarction on the pretreatment CT scan.2
Differences between the ECASS-I and NINDS trials include the treatment window (6 h vs 3 h), the dose of tPA (1.1 mg/kg vs 0.9 mg/kg), and the rigid BP parameters dictated by the NINDS protocol.1 In NINDS, half of the patients (> 300) were enrolled < 90 min from symptom onset, and a post hoc analysis has shown that patients treated early had better outcomes than those treated later. In ECASS-I,2 the median time to treatment was 4.3 h; only 92 patients were enrolled within 3 h of stroke onset.
The ECASS-II trial3 was designed to test the same dose of tPA (alteplase) used in the NINDS trial (0.9 mg/kg with a maximum total dose of 90 mg), but with a 6-h treatment window. A total of 800 patients were randomized in a double-blind fashion to treatment with IV tPA (n = 409) or placebo (n = 391). Concomitant antithrombotic agents were prohibited during the first 24 h, except for low-dose subcutaneous heparin. BP parameters were carefully controlled as in the NINDS trial. Investigators had to successfully complete a standardized CT training program.
The primary end point was the mRS at 90 days, dichotomized as a favorable (mRS, 0 or 1) or unfavorable (mRS, 2 to 6) outcome. In the intention-to-treat analysis, 40.3% of tPA-treated patients (n = 165) had a favorable outcome vs 36.3% of placebo-treated patients (n = 143; absolute difference, 3.7%; p = 0.277). A post hoc analysis of mRS scores dichotomized for independence (favorable mRS, 0 to 2) or death and dependency (mRS, 3 to 6) showed favorable outcomes in 54.3% of patients (n = 222) treated with tPA vs 46% of patients (n = 180) in the placebo group (absolute difference, 8.3%; p = 0.024). There were no differences in the death rates: 10.3% with tPA and 10.5% with placebo. Symptomatic intracranial hemorrhage occurred in 8.8% of the tPA-treated patients vs 3.4% in placebo-treated patients.
The differences in efficacy between the NINDS trial and ECASS-II may be explained by differences in the patient populations and the treatment window. ECASS-II patients had milder strokes on average than the NINDS trial patients. The median baseline NIHSS scores in ECASS-II were 11 in both groups vs 14 and 15 for tPA and placebo treatments, respectively, in NINDS. In ECASS-II,3 only 158 patients received study drug within 3 h of symptom onset. In the NINDS trial,1 patients were treated in < 3 h, with half of the patients receiving treatment in < 90 min.
The ATLANTIS trial was initiated in 1991 to evaluate the safety and efficacy of IV recombinant tPA in patients with ischemic stroke of < 6 h duration (part A). In 1993, the study was changed to 0 to 5 h (part B) due to safety concerns in the 5- to 6-h group.7 In 1996, following FDA approval of tPA in the first 3 h, part B was modified to a 3- to 5-h window. The protocol was similar to the NINDS study except for the time windows. A total of 142 patients were randomized in part A, and an intent-to-treat population of 613 was randomized in part B. Analysis of the target population is based on the 547 patients in part B who were actually treated within the 3- to 5-h window. The trial was terminated in July 1998 because an interim analysis suggested that detection of a beneficial effect of tPA was highly unlikely. In the target population, 32% of placebo-treated patients and 34% of tPA-treated patients had an excellent recovery at 3 months (p = 0.65). The rate of symptomatic intracerebral hematoma (ICH) was 1.1% with placebo vs 7.0% with tPA (p = 0.001). The 90-day mortality rate was 6.9% with placebo and 11.0% with tPA. Intention-to-treat analysis yielded similar results. The investigators concluded that the use of tPA beyond 3 h was not supported by this study. In the ATLANTIS trial,7 the median time to treatment with tPA was 4 h and 35 min and the mean baseline NIHSS was 11. In comparison to the NINDS study, the patients in the ATLANTIS trial had milder strokes on average and were treated quite late.
See Table 1 for a comparison of the key outcomes of NINDS, ECASS-I, ECASS-II, and ATLANTIS part B.
|
MAST-Italy6 was stopped after 622 patients were randomized to treatment within 6 h of stroke-symptom onset. Treatment consisted of IV streptokinase, 1.5 million U given over 1 h; aspirin, 300 mg/d for 10 days; both drugs; or control treatment. The 10-day mortality rate was significantly higher in the streptokinase groups (27% vs 12%; OR, 2.7; 95% CI, 1.7 to 4.4) and was highest (34%) in patients who received both streptokinase and aspirin. The early mortality rate with streptokinase alone was 19% compared with 13% in the placebo-treated group. The rate of symptomatic intracranial hemorrhage was 6% in streptokinase-treated patients, 10% in those who received combined therapy, 2% in patients receiving only aspirin, and 0.6% in the control group. There was a nonsignificant reduction in death and disability at 6 months in patients treated with streptokinase.
Before the safety committee halted the trial, MAST-Europe4 randomized 270 patients with stroke of < 6-h duration. Patients were treated with streptokinase (1.5 million U) or placebo. Symptomatic intracranial hemorrhage occurred in 17.5% of patients in the streptokinase group and 3.0% of the placebo group. The 10-day mortality rates were 35% with streptokinase vs 18% with placebo.
The Australian Streptokinase Trial5 randomized 340 patients within 4 h of stroke onset to receive either streptokinase (1.5 million U over 1 h) or placebo. This trial was abandoned because of an increase in mortality and disability in the streptokinase-treated group, particularly in patients treated > 3 h after symptom onset.
The streptokinase trials demonstrate convincingly that there is an increase in early mortality and symptomatic intracerebral hemorrhage when a dose of 1.5 million U of streptokinase is given during a 6-h window after symptom onset. Patients given a combination of streptokinase and aspirin had the worst outcomes.
Intra-arterial Thrombolysis Studies: Intra-arterial thrombolytic therapy may be delivered either by regional infusion or by local infusion directly into the thrombus using supraselective catheters. These approaches have the potential advantages of increased recanalization rates, improving the accuracy of diagnosis, and perhaps enhanced safety because of a reduction in the total dose of drug administered. Disadvantages include the limited availability of facilities and of personnel who are capable of performing intra-arterial therapy, and the inherent delays in drug administration related to the logistics of assembling an appropriate team and performing angiography.
The PROACT trial8 treated 40 patients with MCA occlusions with either intra-arterial rpro-UK (n = 26) or placebo (n = 14). All patients received IV heparin. Treatment with the study drug was started a median of 5.5 h after symptom onset. Recanalization rates were significantly higher with rpro-UK (58%) than with placebo (14%; two-tailed p = 0.017). There was no significant difference in the rate of early symptomatic hemorrhagic transformation, which occurred in 15.4% of the rpro-UK-treated patients and 7.1% of the placebo-treated patients (2p = 0.64). Mortality rates and clinical outcomes at 90 days favored treatment with rpro-UK but did not reach statistical significance. Recanalization rates and the risk of brain hemorrhage were influenced by the dose of heparin.
PROACT II9
was designed to further test the efficacy and
safety of intra-arterial rpro-UK in patients with MCA occlusion of
< 6-h duration. More than 12,000 patients were evaluated for
inclusion in the trial, and 474 patients underwent a screening
conventional cerebral angiogram. A total of 180 patients had
angiographically confirmed MCA occlusions and were randomized to
receive 9 mg of intra-arterial rpro-UK plus heparin (n = 121) or
heparin alone (n = 59). The heparin dose was the same for both groups
(2,000-U bolus and a 500-U/h infusion of heparin for 4 h). A
clinically and statistically significant benefit favored rpro-UK in the
primary outcome analysis, with 40% of treated patients recovering to a
mRS of 
2 compared with 25% of control patients (absolute risk
reduction, 15%; p = 0.043; relative risk reduction, 60%). Mortality
was 25% in the rpro-UK arm and 27% in the control group. Symptomatic
intracranial hemorrhage occurred in 10% of rpro-UK-treated patients
and 2% of control patients (p = 0.063). The recanalization rate
(Thrombolysis In Myocardial Infarction35a
grade 2 or 3
flow rates) was 66% for rpro-UK vs 18% for control
(p < 0.001).
Patients recruited to PROACT II9 had moderate to severe strokes, with a median baseline NIHSS of 17. The median time to start of intra-arterial treatment was 5.3 h. Mechanical clot disruption was not permitted.
At present, use of intra-arterial thrombolytic therapy for ischemic stroke has not received FDA approval and should be limited to clinical trials or highly selected patients who provide informed consent. Intra-arterial thrombolysis should be administered only by physicians with expertise in stroke and neurointervention techniques. An integrated multidisciplinary effort is required to permit the early recognition and timely treatment of patients. Additional clinical trials are needed to identify optimal patient characteristics for intra-arterial therapy and to better define the safety, efficacy, and the most effective agents, doses, and delivery techniques.
Meta-analysis of Thrombolytic Therapy: Thrombolytic stroke trials are extraordinarily difficult to conduct and, to date, only modest numbers of patients have been evaluated. Meta-analysis, when appropriately applied to trials using similar agents and therapeutic windows, is useful to define risks and benefits of specific therapies.
Meta-analysis of trial results for patients treated with tPA within 3 h of symptom onset (n = 866) showed a very significant reduction in the rate of death or dependency, from 71.6% in control-treated patients to 57.7% with tPA (OR, 0.55; 95% CI, 0.41 to 0.72).36 This benefit translates to one additional independent survivor for every seven patients treated. Similar results were obtained in the Cochrane Systematic Review of treatment with tPA within 3 h.37 IV tPA given within 6 h of symptom onset (n = 2,764) also showed significant, though less robust, benefit with a reduction in death or dependency from 57% in the control group compared to 51% in the tPA-treated group (OR, 0.79; 95% CI, 0.68 to 0.92; p = 0.002). The benefits with a 6-h window occurred despite the increase in symptomatic intracranial hemorrhage from 3% in control subjects to 10% in treated patients (OR, 3.2; 95% CI, 2.4 to 4.3).
The Cochrane Stroke Review Group conducted a meta-analysis37 of 17 trials involving a total of 5,216 patients conducted since 1981, evaluating a variety of thrombolytic agents, regimes, and therapeutic windows. Overall, thrombolytic therapy was associated with an excess of early deaths (OR, 1.85; 95% CI, 1.48 to 2.32) and early symptomatic hemorrhages (OR, 3.53; 95% CI, 2.79 to 4.45). Despite the risks of hemorrhage, there was a reduction in death or dependency when thrombolytic therapy was administered within 6 h (OR, 0.83; 95% CI, 0.73 to 0.94). Considerable heterogeneity existed between trial protocols, with one study entering patients only in the first 90 min or 180 min after stroke onset, while others entered patients as late as 5 days or 2 weeks after onset.
Use of IV tPA in Clinical Practice: Published reports of clinical experience with tPA administered according to protocols similar to the NINDS trial have, in general, demonstrated safety profiles and rates of favorable outcome that mirror the NINDS results. In the Standard Treatment with Activase to Reverse Stroke study,38 the largest series reported, the rate of symptomatic intracerebral hemorrhage was 3% in 389 patients treated in academic and community medical centers. Others have reported symptomatic intracranial hemorrhage rates of 5.8% of 189 tPA-treated patients and rates of 7%39 and 6.6%40 in smaller studies. These complication rates compare favorably to the 6.4% symptomatic intracranial hemorrhage rate in the NINDS trial.1 Strict adherence to treatment protocols is strongly recommended to achieve a favorable risk-benefit profile. Recently, three patients have been described who received tPA for stroke treatment within a few days of symptoms suggestive of cardiac ischemia.41 These patients developed hemopericardium and life-threatening cardiac tamponade. Therefore, a careful history, searching for symptoms of recent myocardial ischemia or pericardial disease, may be appropriate prior to administering tPA for stroke treatment.
Evaluation of Baseline CT Scan
A technically adequate head CT scan is required prior to
administration of thrombolytic therapy to exclude brain hemorrhage and
nonischemic diagnoses. The baseline CT scan is also sensitive for
detection of early signs of cerebral infarction. Patients with early
radiographic evidence of major cerebral infarction defined as the
presence of mass effect or ischemic hypodensity involving greater than
one third of the MCA territory are at substantially greater risk for
developing symptomatic intracranial hemorrhage following thrombolytic
therapy1
2
and have been excluded from several large
randomized trials (ECASS-I, ECASS-II, PROACT-II, ATLANTIS). In general,
these patients should not receive tPA therapy.
Subtle or limited signs of early infarction on the CT scan are common and do not preclude the safe use of tPA for stroke treatment. These signs include blurring of the internal capsule, loss of clarity of the lentiform nucleus, loss of differentiation between cortical gray matter and subcortical white matter (eg, loss of the insular ribbon), and mild sulcal effacement.
The use of MRI rather than CT for selection of patients for thrombolytic therapy is under investigation. Preliminary data42 suggest that specific MRI profiles may identify patients who are particularly likely to benefit from thrombolytic therapy. In addition, MRI appears to be highly sensitive for identification of acute brain hemorrhage.43 44
Defibrinogenating Agents in Acute Stroke
Ancrod is a thrombin-like defibrinogenating agent derived
from a purified snake venom fraction, with a unique pharmacologic
profile that may benefit patients with acute ischemic stroke. The
depletion of fibrinogen produces effective anticoagulation and inhibits
platelet aggregation. The reduction in fibrinogen also serves to reduce
blood viscosity, thereby potentially increasing cerebral blood flow.
Additionally, the products of defibrinogenation indirectly stimulate
endogenous plasminogen activators, which may enhance clot lysis. Small
ischemic stroke studies45
46
47
have demonstrated outcome
trends favoring ancrod.
The STAT study48
randomized 500 patients to ancrod or
placebo treatment initiated within 3 h of symptom onset. Treatment
was given as a continuous 72-h infusion, followed by 1-h infusions at
96 h and 120 h. Ancrod dose adjustments were made to target
plasma fibrinogen levels from 40 to 69 mg/dL. The primary efficacy end
point was a BI of 
95. The covariate-adjusted proportions of
functional success were 42.2% in the ancrod-treated group vs 34.4% in
placebo-treated patients (p = 0.041). Mortality rates were similar in
the two groups. Symptomatic intracranial bleeding occurred in 5.2% of
ancrod-treated patients and 2% of placebo-treated patients
(p = 0.063).48
Ancrod has not been approved by the FDA
and remains investigative therapy. The European Stroke Treatment with
Ancrod Trial is in progress and is designed to evaluate ancrod vs
placebo treatment in 1,680 patients randomized to treatment within
6 h of symptom onset.
1.2. Patients Not Eligible for Thrombolysis
For acute cerebral infarction patients who are not eligible for IV
recombinant tPA therapy, a variety of antithrombotic agents can be
considered. Several anticoagulants (heparin, low-molecular-weight
heparins, and heparinoids) and aspirin have been evaluated in clinical
trials. The rationale for the use of antithrombotic therapy for
treatment of acute ischemic stroke is based on two premises: (1)
reduction of the risk of stroke progression or recurrent cerebral
thromboembolism; and (2) prevention of venous thromboembolic
complications such as deep venous thrombosis (DVT) and pulmonary
embolism (PE).
The use of antithrombotic agents in an attempt to reduce the risk of stroke progression or recurrent embolism is complicated by the existence of different stroke etiologic subtypes, each of which imparts a differential risk of these outcomes. The therapeutic approach to the acute stroke patient should consider these distinct pathophysiologic mechanisms. Unfortunately, in the early hours of presentation with an acute stroke, the mechanism of the infarction is frequently not clear and decisions regarding therapy are based on presumptive diagnostic subtypes.
Subtypes of Ischemic Stroke: Strokes caused by large-artery atherosclerosis appear to have the greatest risk of worsening and recurrence in the early period after hospitalization. In the NINDS Stroke Data Bank,49 the atherosclerotic stroke subgroup had a 30% risk of worsening during the acute hospitalization and a 7.9% risk of stroke recurrence within 30 days. In the North American Symptomatic Carotid Endarterectomy Trial,50 medically treated patients with transient ischemic attack (TIA) or stroke and ipsilateral carotid stenosis > 70% had a 26% risk of ipsilateral stroke at 2 years. Data from the Northern Manhattan Stroke Study51 indicated that the 30-day risk of recurrence was 8% for patients with extracranial atherosclerosis and 7.1% for those with intracranial atherosclerosis. These risks were nearly sixfold greater than those for nonatherosclerotic stroke.51 Moreover, recurrent stroke risks from natural history studies are generally greater than those observed in the control groups of recent randomized trials that reported risks of 0.6 to 2.2%/wk.52
Causes of worsening and recurrence in patients with large artery atherosclerotic stroke include propagation or progression of the thrombosis, distal embolism, or failure of collateral vessels to compensate for the reduced cerebral perfusion. For these reasons, anticoagulation has been advocated as a rational approach for these patients on the basis of theoretical pathophysiologic considerations despite the absence of supportive clinical trial evidence.
Progressing stroke (also referred to as "stroke in evolution") has frequently been considered an indication for anticoagulation, although supportive randomized clinical trial data are scant. Studies performed in the 1950s and 1960s suggested that IV heparin therapy may be beneficial for patients with unstable ischemic stroke with as much as a 50% reduction in the likelihood of further worsening.53 54 55 56 57 Many of these studies, however, were not randomized or blinded, had poorly defined inclusion and exclusion criteria, and did not use standardized assessments for outcomes.58 More recent nonrandomized studies of consecutive patients with unstable stroke who received IV heparin have shown high rates (27 to 50%) of further progression despite treatment.59 60 61
For cardioembolic strokes, older studies suggested a recurrence risk that approached 1%/d in the first 14 days; however, more recent studies have found the risk of early recurrence to be considerably lower.49 62 63 64 The cause of an early recurrence in patients with cardioembolic stroke is usually another thrombus becoming dislodged from the intracardiac source, and the risk of early stroke recurrence is likely related to the underlying cardiac lesion. For example, one study65 found a high rate of early recurrence in a large group of cardioembolic stroke patients who had rheumatic heart disease, prosthetic valves, or documented intracardiac thrombi, but a significantly lower recurrence rate in atrial fibrillation patients.66
Anticoagulants substantially reduce the risk of cardiac embolism, but the evidence supporting the use of anticoagulation in patients with acute cardioembolic stroke is based on limited data from case series and a single small randomized clinical trial.67 The randomized trial was terminated early after only 45 patients were enrolled. No early recurrence occurred in the group who received anticoagulants, compared with a 10% recurrence rate (2 of 20) in the patients who did not receive anticoagulants. More recent clinical trials have cast doubts on the efficacy of early anticoagulation for strokes with a cardioembolic source. For example, the recently published Heparin in Acute Embolic Stroke study68 randomized 449 patients with acute ischemic stroke (within 30 h after onset) to treatment with aspirin (160 mg/d) vs a high dose of the low-molecular-weight heparin, dalteparin (100 IU/kg subcutaneously bid). No difference in the frequency of early recurrent ischemic stroke or cerebral hemorrhage was detected. The timing of administration of IV anticoagulation can affect the risk-to-benefit ratio. Minimizing the risk of hemorrhagic transformation of an infarct while maximizing the reduction in early recurrence are the aims of early anticoagulation. A large infarct size, judged by neuroimaging findings or the clinical syndrome, and elevated BPs are predictors of a greater risk of hemorrhagic transformation and warrant a delay in the use of anticoagulation.69
Infarcts caused by small artery occlusions (lacunar strokes) have the lowest early recurrence risk and the best survival rates, but still cause significant functional morbidity. Worsening or evolution of the infarct can occur, although motor deficits improve to a greater extent in strokes due to small artery occlusions compared to nonlacunar stroke syndromes.70 The underlying mechanism in the majority of lacunar strokes arises from small vessel disease, usually caused by lipohyalinosis.71 Thrombosis, as well as platelet-fibrin complexes, can lead to occlusion after the small vessel lumen has been significantly narrowed. Large vessel atherosclerosis and embolism can also lead to small vessel occlusions, but these mechanisms probably occur in < 25% of patients with lacunar syndromes.71
Some strokes are difficult to reliably classify into these categories and have been labeled cryptogenic infarcts. These patients typically have no carotid bruit or TIA ipsilateral to the hemisphere affected by the stroke and no obvious history suggestive of cardiac embolism, and usually do not present with a lacunar syndrome. The CT or MRI scan performed may have normal findings, show an infarct limited to a surface branch territory, or show a large zone of infarction affecting regions larger than can be accounted for by a single penetrant arterial territory. Noninvasive vascular imaging fails to demonstrate an underlying large vessel occlusion or stenosis. No cardiac source of embolism is uncovered by echocardiography, ECG, or Holter monitoring.
For those infarcts considered cryptogenic, theoretical considerations favor the diagnosis of an embolism despite the absence of a definitive source.72 Some experts treat these patients as though they have an acute cardiac embolism until the diagnostic cardiac testing is completed. Emerging technologies have led to the suggestions that some cryptogenic infarcts may be explained by hematologic disorders causing hypercoagulable states, paradoxical emboli through a patent foramen ovale (PFO), unrecognized arterial lesions (dissections, mild atherosclerosis), or aortic arch atherosclerosis.73 74 75 Optimal antithrombotic therapy for these etiologies has not been evaluated in randomized trials. Decisions about acute therapy for cryptogenic infarcts depend on a presumed mechanism for the stroke.
Recent Studies of Anticoagulants for Acute Stroke Therapy: Randomized trials using heparin, heparinoids, and aspirin have helped clarify the benefits and risks of antithrombotic agents for treatment of acute ischemic stroke.
Since 1980, to our knowledge, only a single randomized trial76 has evaluated IV heparin compared with placebo treatment for patients with acute stable stroke. No significant difference in stroke progression or neurologic outcome was detected in this relatively small study (n = 225). This trial had a broad treatment window of 48 h from stroke onset and excluded patients with progressing stroke. In addition, because of the small sample size, the study had adequate power to detect only a relatively large difference in efficacy between heparin and placebo treatment.
Subcutaneous administration of heparin was evaluated in the International Stroke Trial (IST).63 In this unblinded megatrial, 19,435 patients with suspected acute ischemic stroke from 467 hospitals in 36 countries were randomized within 48 h of onset (median, 19 h) to treatment with aspirin, subcutaneous heparin, both, or neither in a factorial design. Half were allocated 300 mg of aspirin and half to "avoid aspirin"; half were allocated unfractionated heparin (administered subcutaneously in two different doses of 5,000 U bid or 12,500 U bid), and the remaining half to "avoid heparin." In this study, therapy could be started before a CT scan was obtained to verify that the stroke was not hemorrhagic (this occurred in one third of the cases) and the level of anticoagulation achieved was not monitored. The patients were followed up by the local investigators until hospital discharge or for 14 days, whichever was sooner, and at 6 months by telephone or postal questionnaire by each national coordinating center. The primary outcomes were death within 14 days, and death or dependency at 6 months. Secondary outcomes included recurrent ischemic stroke, hemorrhagic stroke, PE, or transfused or fatal extracranial hemorrhage within 14 days.
IST data were analyzed with the two heparin groups combined. There was no significant difference in 14-day mortality (heparin, 9.0% vs no heparin, 9.3%) or 6-month outcome (heparin, 62.9% dead or dependent vs no heparin, 62.9%). At 14 days, recurrent ischemic strokes were significantly reduced in the heparin groups (from 3.8 to 2.9%) but hemorrhagic stroke was significantly increased (from 0.4 to 1.2%), yielding no net benefit. In the subgroup of patients who presented with atrial fibrillation and acute ischemic stroke, heparin significantly reduced the risk of 14-day ischemic stroke recurrence from 4.9 to 2.8%, but an increased risk of hemorrhagic stroke (2.1% vs 0.4%) neutralized the potential benefits. Transfused or fatal extracranial hemorrhages were significantly more frequent among those allocated to heparin therapy. The higher-dose regimen (12,500 U bid) was associated with more systemic bleeding, hemorrhagic strokes, and a significantly increased risk of death or nonfatal stroke at 14 days. The low-dose heparin regimen (5,000 U bid) significantly reduced the risk of early death or nonfatal stroke, with only a slight and nonsignificant excess of bleeding side effects. As shown in Figure 4 , patients who received both low-dose heparin and aspirin had the lowest rate of stroke recurrence, or PE, and no significant increase in bleeding risk (compared with patients who received low-dose heparin without aspirin). In summary, the heparin data from IST suggest that the use of early unmonitored subcutaneous heparin will reduce early stroke recurrence risks, but these benefits can be eliminated by increased hemorrhagic complications. The use of lower doses of heparin may provide more benefits than hemorrhagic side effects.
|
The Trial of ORG 10172 in Acute Stroke Treatment (TOAST)64
evaluated the low-molecular-weight heparinoid danaparoid (ORG 10172)
among 1,281 patients with ischemic stroke treated within 24 h of
onset. In this multicenter, blinded, placebo-controlled trial, patients
were treated for 7 days with an IV infusion of the heparinoid, and
daily dose adjustments were based on antifactor Xa units. The mean time
between symptom onset and treatment was 15.5 h. Neurologic
deficits were evaluated daily using the NIHSS. The primary outcome was
based on the 3-month assessment of the GOS and the BI, with a favorable
status defined as GOS of 1 or 2 and BI of 60. Overall, there was no
significant difference in the proportion of patients with favorable
outcomes at 3 months in the danaparoid group compared with the placebo
group (75.2% vs 73.7%; Fig 5
). Favorable outcomes at 7 days were slightly increased in the
danaparoid group compared with the placebo group (59.2% vs 54.3%;
p = 0.07), while the number of patients with very favorable
outcomes was significantly higher in the danaparoid group (33.9% vs
27.8%; p = 0.01). There was no significant reduction in stroke
progression, 7-day mortality, or the risk of stroke recurrence or
systemic embolic events. Subgroup analysis revealed a benefit in
favorable outcome at 3 months for patients with large artery
atherosclerotic stroke (68.1% vs 54.7%; p = 0.04). This subgroup
analysis offers some evidence in favor of the efficacy of heparinoids
for treatment of acute large artery atherosclerotic stroke; however,
this finding should be verified in additional studies.
|
Use of Antiplatelet Agents in Acute Stroke: Aspirin is the only antiplatelet agent that has been evaluated for the treatment of acute ischemic stroke. Data are now available from two recent large trials, the IST63 and the Chinese Acute Stroke Trial (CAST).80 These studies both found that the use of early aspirin in patients treated within 48 h of stroke onset (median time to randomization was 19 h in IST, and the mean time to randomization was 25 h in CAST) reduced both stroke recurrence risk and mortality.63 80 Among 19,435 patients randomized in IST, aspirin-allocated patients had slightly fewer deaths within 14 days (9.0% vs 9.4%), significantly fewer recurrent ischemic strokes (2.8% vs 3.9%), no excess of hemorrhagic strokes (0.9% vs 0.8%), and a trend toward a reduction in death or dependence at 6 months (61.2% vs 63.5%).
In CAST,79 21,106 patients with acute ischemic stroke within 48 h of onset were randomized to receive 160 mg/d of aspirin or a placebo for up to 4 weeks. The primary end points were death from any cause at 4 weeks and death or dependence at hospital discharge. The majority of patients (87%) had a CT scan before randomization. There were small but significant reductions in the aspirin group in both early mortality (3.3% vs 3.9%; p = 0.04) and recurrent ischemic strokes (1.6% vs 2.1%; p = 0.01). At hospital discharge, there was a smaller proportion of patients who were dead or dependent in the aspirin-treated group (30.5% vs 31.6%; p = 0.08). In combination, the IST and CAST trials demonstrate that the use of aspirin in the treatment of acute ischemic stroke is safe and produces a small but definite net benefit. For every 1,000 acute strokes treated with aspirin, about 9 deaths or nonfatal stroke recurrences will be prevented in the first few weeks and approximately 13 fewer patients will be dead or dependent at 6 months.
Antithrombotic Therapy for Prevention of DVT and PE: DVT and PE are frequent complications of stroke, with about 5% of early deaths attributed to PE.81 Large trials performed in other high-risk groups (such as patients who underwent major surgery) indicate that heparin can reduce the risk of DVT and PE by about 60%.81a For acute stroke patients, few randomized trials have individually been able to demonstrate a significant decrement in the risk of these complications. An overview analysis82 in 1993 reviewed the results of 10 trials that evaluated heparin in 1,047 patients with acute ischemic stroke; an 80% reduction in DVT and a 58% reduction in PE were found. In the IST,63 there was a significant reduction in the frequency of fatal or nonfatal PE, from 0.8 to 0.5%, among those treated with heparin (p < 0.05). Aspirin therapy was not effective for preventing PE in this study. Low-molecular-weight heparins have been found to be equivalent to or better than unfractionated heparin in preventing DVT (see chapter on prevention of venous thromboembolism). In the TOAST study,64 DVTs were significantly reduced in the heparinoid-treated group compared with the placebo-treated group. DVT and PE prophylaxis is an essential reason to consider early anticoagulant therapy in acute stroke patients.83 For patients with contraindications to anticoagulants, intermittent pneumatic compression devices or elastic stockings are recommended (see chapter on prevention of venous thromboembolism).
DVT/PE Prophylaxis in Patients With ICH: Only one small study is available to address the risk of early prophylactic therapy with anticoagulants in patients with intracerebral hemorrhages.83a In this study, 22 patients with spontaneous intracerebral hemorrhage were treated with subcutaneous heparin beginning on the second day after the ICH. When compared with historical control subjects, early (day 2) low-dose heparin therapy (5,000 U heparin sodium tid subcutaneously) significantly lowered the incidence of PE compared with delayed (day 4 or day 10) heparin therapy. No increase in the number of patients with rebleeding in the brain was observed. These results suggest that the early use of low-dose heparin may be safe and effective in ICH patients.
|
2. STROKE PREVENTION |
|---|
|
TOPIntroduction1. acute ischemic stroke...2. stroke prevention 3. cerebral venous sinus...RecommendationsReferences |
|---|
The Antiplatelet Trialists81 conducted a major meta-analysis that assessed the effect of antiplatelet agents in patients with various manifestations of atherosclerosis. These studies included patients with unstable angina, MI, TIA, and stroke, as well as other patients at increased risk for atherothrombotic events. They aggregated the 73,247 high-risk patients who had been in trials lasting > 30 days, ie, receiving long-term antiplatelet therapy. The Antiplatelet Trialists emphasize the composite outcome of stroke, MI, or vascular death. This outcome cluster includes hemorrhagic stroke and death due to hemorrhage. They also analyzed nonfatal stroke, nonfatal MI, vascular death, and death from any cause independently. They express the treatment effects for the various vascular outcomes as odds reductions.
The Antiplatelet Trialists found that overall (in all kinds of patients at high risk for vascular outcomes), antiplatelet agents reduce the odds of the composite outcome of stroke, MI, or vascular death in secondary prevention by about 27%. The odds reduction attributable to aspirin alone was 25%. They found that antiplatelet agents reduce the odds of a nonfatal stroke by 31%, nonfatal MI by about 35%, and vascular mortality by 18%.
The Antiplatelet Trialists also analyzed the differences in the response of patients > 65 and < 65 years old, and by sex. While some variation is seen, all groups (young and old, men and women) benefit to a similar proportionate degree from antiplatelet therapy. The same is true for patients with hypertension compared with those without hypertension, and diabetes compared with no diabetes.
An important issue arising from the Antiplatelet Trialists’ analyses is whether the effect of various antiplatelet agents on prevention of strokes, MIs, and vascular deaths is the same in patients entering studies because of prior stroke/TIA as it is for patients entering because of prior MI or other vascular disorders. The Antiplatelet Trialists found that whereas "all antiplatelet agents" reduced the odds of stroke, MI, or vascular death in "all high-risk patients" by 27%, the odds reduction in patients with prior stroke/TIA was only 22%.81 Additionally, Algra and van Gijn84 performed a mini-meta-analysis showing that in the 10 trials that evaluated the benefit of aspirin alone in patients who had prior stroke or TIA, aspirin reduced the odds for the cluster of stroke, MI, or vascular death by only 16%. When this odds reduction is converted to the more conventional relative risk reduction, the benefit over placebo is only 13%.
Differences in antiplatelet effects in different populations of patients may occur because the etiologic mechanisms for stroke may differ, or stroke patients may have a higher rate of recurrent strokes, which may be more difficult to prevent than MIs. For this review, we will focus on patients with prior stroke or TIA, and for outcome events we will emphasize stroke alone, and the cluster of stroke, MI, or vascular death.
Aspirin: The Swedish Aspirin Low-Dose Trial85 compared aspirin, 75 mg/d, with placebo treatment in 1,360 patients with minor stroke/TIA. The 18% relative risk reduction in stroke plus all death in the aspirin-treated group was statistically significant (p = 0.02). The relative risk reduction in stroke, MI, or vascular death was 17%, and was also statistically significant. This degree of risk reduction is comparable to the 13% that Algra and van Gijn84 found for all doses of aspirin in similar patients.
The Dutch TIA Trial86 compared two dosage regimens of aspirin, 30 mg/d vs 273 mg/d, in 3,131 patients with minor stroke/TIA. The primary outcome measure was stroke, MI, or vascular death. The investigators found that aspirin, 30 mg/d, was no less effective than 273 mg/d, and there were fewer bleeding events with the lower dose.
These latter two trials, along with the earlier United Kingdom Transient Ischaemic Attack trial87 and the Algra and van Gijn mini-meta-analysis,84 led many clinicians to believe there are no important differences in daily doses of aspirin between 30 mg and 1,300 mg for preventing stroke and other vascular events. Also, low-dose aspirin is less gastrotoxic. Then in 1996, the European Stroke Prevention Study (ESPS)-II88 (see below) reported that aspirin, 50 mg/d, administered to patients following stroke or TIA reduced the risk of stroke, and stroke or death, by 18% and 13%, respectively. Consequently, the majority of clinicians worldwide currently recommend a daily dose of 325 mg or less for prevention of stroke. The acceptable dose range of aspirin for stroke prevention includes daily doses from as low as 30 mg to as high as 1,300 mg.89 In 1998, the FDA published their new recommendation that aspirin, 50 to 325 mg/d, be used for prevention of ischemic stroke.90
One additional direct comparison of low and high aspirin doses was recently studied in patients undergoing carotid endarterectomy (the ASA and Carotid Endarterectomy [ACE] trial).91 ACE compared, head-to-head, aspirin at low doses (81 mg/d or 325 mg/d) vs high doses (650 mg/d or 1,300 mg/d) in 2,804 patients treated for a total of 3 months. There were no significant differences between low and high doses for any end point at 30 days, or for the end points of stroke and death, and ipsilateral stroke and death at 3 months. Patients who received low-dose aspirin had a significantly lower rate of stroke, MI, and death at 3 months (p = 0.03). The ACE results lend further direct support to the premise that low-dose aspirin is at least as effective as high-dose aspirin.
Data from numerous trials establish that aspirin reduces the risk of stroke, MI, and vascular death in a wide variety of patients who are at high risk for these atherothrombotic outcomes. There is a trend toward patients with stroke/TIA benefiting less than other high-risk patients. There also is a trend toward stroke/TIA patients experiencing a smaller reduction in nonfatal strokes than other high-risk patients. More data are necessary to determine if these trends are real.
Ticlopidine: Ticlopidine hydrochloride is a thienopyridine that inhibits adenosine diphosphate-induced fibrinogen binding to platelets, a necessary step in the platelet aggregation process. It has been shown to be effective for the prevention of vascular outcomes in several randomized studies.91a Two large trials92 93 assessed ticlopidine for the prevention of stroke and other vascular events in patients presenting with cerebrovascular symptoms.
The Ticlopidine Aspirin Stroke Study (TASS)92 enrolled 3,069 patients who presented within 3 months of suffering a minor stroke or TIA. Half were treated with aspirin, 650 mg bid, and half were treated with ticlopidine, 250 mg bid. The ticlopidine group had a 21% greater relative risk reduction for stroke compared with aspirin, and a 9% greater reduction in the end point cluster of stroke, MI, or vascular death at 3 years (intention-to-treat analysis).94
Serious GI adverse effects (eg, ulcers and bleeding) were 2.5 times more common in the aspirin group even though patients who had any history of GI hemorrhage or dyspeptic symptoms were excluded from the trial. Bleeding from other anatomic sites was infrequent and about equal in the two treatment groups. Two percent of the patients receiving ticlopidine were unable to tolerate the medication because of diarrhea, and another 2% because of skin rash. Severe neutropenia occurred in 0.9% of patients in the ticlopidine-treated group. Neutropenia reversed with cessation of treatment and almost always occurred within 2 to 3 months after treatment began. Because of the high incidence of neutropenia, blood counts are required at 2-week intervals for the first 3 months of ticlopidine therapy (ie, six blood counts in 3 months).
The Canadian American Ticlopidine Study93 involved 1,072 patients who were enrolled after the occurrence of a major ischemic stroke. The patients were randomly allocated to treatment with ticlopidine, 250 mg bid, or matching placebo. Patients in this study who received placebo had an event rate for stroke, MI, or vascular death of 15.3%/yr, demonstrating the seriousness of stroke as a predictor of subsequent vascular events. Ticlopidine reduced the relative risk of stroke, MI, or vascular death by 30%, to 10.8% (p = 0.006), in the on-treatment analysis. The same outcome cluster was reduced by 23% (p = 0.020) in the ticlopidine group using the intent-to-treat approach. Adverse effects were similar to those noted in TASS. Ticlopidine reduced the relative risk of ischemic stroke by 33.5% (p = 0.008) in the on-treatment analysis.
Taken together, these trials show that ticlopidine substantially reduces the risk of stroke and other vascular outcomes in patients with cerebrovascular disease, and TASS showed ticlopidine to be more effective than aspirin. Ticlopidine appears to be about 20% better than aspirin in reducing stroke, and about 10% better than aspirin in reducing the composite outcome of stroke, MI, or vascular death. Ticlopidine is associated with an approximately 1% incidence of severe neutropenia and > 60 cases of ticlopidine-associated thrombotic thrombocytopenia purpura (TTP) have been reported.95 96
The risk of ticlopidine-related adverse effects appears to be lower in nonwhite populations.97 In addition, subgroup analysis of the TASS study suggested that African-American patients were more likely to benefit from ticlopidine than white patients.97 The African American Antiplatelet Stroke Prevention study is currently enrolling 1,800 African Americans into a multicenter, randomized, double-blind trial comparing ticlopidine, 500 mg qd, vs aspirin, 650 mg qd.98
Clopidogrel: Clopidogrel is a thienopyridine derivative of the same chemical family as ticlopidine. It is a potent inhibitor of platelet aggregation induced by adenosine diphosphate. Its antithrombotic effects were evaluated in the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study.99 CAPRIE was a randomized, blinded, multicenter trial designed to assess the relative efficacy of clopidogrel (75 mg/d) and aspirin (325 mg/d) in reducing the risk of the composite outcome of ischemic stroke, MI, or vascular death, and to determine their relative safety. Three groups of patients were studied: those with recent ischemic stroke, recent MI, and symptomatic peripheral arterial disease.
In 19,185 patients (> 6,000 in each of the three groups), the intention-to-treat analysis showed that patients treated with clopidogrel experienced a 5.32% annual risk of ischemic stroke, MI, or vascular death, vs 5.83% with aspirin, for a relative risk reduction of 8.7% in favor of clopidogrel (95% CI, 0.3 to 16.5; p = 0.043), and an absolute risk reduction of 0.5%. The corresponding on-treatment analysis showed a relative risk reduction of 9.4%. When serious hemorrhages were considered along with the primary outcome cluster in an intent-to-treat analysis, which provides a true net-benefit assessment, the relative risk reduction with clopidogrel was 9.5% (95% CI, 1.2 to 18.5). Finally, when the results in CAPRIE are analyzed using the Antiplatelet Trialists’ technique (ie, intent to treat; all stroke, MI, or vascular death, including hemorrhagic) and by odds reduction, there is a reduction of 10% favoring clopidogrel.
For the 6,431 patients entered into CAPRIE99 with a stroke as the qualifying condition, the relative risk reduction for ischemic stroke, MI, or vascular death was 7.3% (95% CI, - 5.7 to 18.7; p = 0.26), and the relative risk reduction for the end point of stroke was 8% (95% CI, - 7 to 21; p = 0.28.).
Although there were no major differences between aspirin and
clopidogrel in terms of safety, and adverse experiences were minimal,
serious hemorrhages occurred at a slightly higher rate among patients
taking aspirin (1.55% vs 1.38%). There were 10 patients in the
clopidogrel group (0.10%) with significant reductions in neutrophils
to < 1,200 cells/µL, compared with 16 patients in the
aspirin group (0.17%). Five patients in the clopidogrel group and four
patients in the aspirin group had severe neutropenia (< 450
cells/µL). The overall safety profile of clopidogrel is similar to
that of 325 mg/d of aspirin. A recent report100
identified
11 cases of thrombotic thrombocytopenic purpura (TTP) associated with
clopidogrel among > 3 million patients who have received this agent.
Ten of these 11 cases occurred within 2 weeks of initiation of
clopidogrel therapy, and most responded favorably to plasma exchange,
although two patients required 20 exchanges before clinical
improvement.
The CAPRIE study99 data indicate that clopidogrel is more effective than aspirin in reducing the combined risk of ischemic stroke, MI, or vascular death in patients with atherosclerotic vascular disease. The beneficial effects of clopidogrel for the combined vascular end point seem to be comparable to the effects of ticlopidine, without the negative adverse effects profile. When compared with aspirin, the effect of clopidogrel on reducing stroke appeared to be less than the effect of ticlopidine. This result could be explained by the play of chance. Alternatively, ticlopidine and clopidogrel may prevent strokes differently, the dose of clopidogrel tested may have been suboptimal, or perhaps the benefit of these agents in TIA patients is greater than that in stroke patients.
Dipyridamole: The Antiplatelet Trialists81 analyzed trials involving dipyridamole alone vs placebo, dipyridamole combined with aspirin vs placebo, and dipyridamole combined with aspirin vs aspirin alone.
Ten trials compared dipyridamole alone vs placebo (200 events in 1,474 patients) and showed a 23% odds reduction for stroke, MI, or vascular death favoring dipyridamole. Thirty-four trials (1,741 events in 13,718 patients) compared dipyridamole combined with aspirin vs placebo and showed a 28% odds reduction in stroke, MI, or vascular death favoring the combination.
The Antiplatelet Trialists81 analyzed 14 trials that compared the combination of dipyridamole plus aspirin vs aspirin alone (628 events in 5,317 patients) for prevention of the composite outcome of stroke, MI, or vascular death. One trial involved patients entered because of prior MI, three involved patients entered because of prior stroke/TIA, four because of postcoronary artery bypass grafting, three because of intermittent claudication, two because of noncoronary grafting, and one because of diabetes. The odds reduction for all vascular events was - 3%, indicating a slight (statistically nonsignificant) benefit favoring aspirin alone. The only outcome that was reduced by dipyridamole combined with aspirin was nonfatal stroke. The odds reduction was 12% and not statistically significant. Although there is no signal favoring dipyridamole plus aspirin over aspirin for reducing MI, the number of MIs in trials evaluating this combination is inadequate to conclude no benefit with confidence.
In 1996, the results of the ESPS-288 were published. Patients who had experienced either an ischemic stroke or TIA were studied in a multicenter, randomized, blinded, factorial, placebo-controlled study with four treatment groups and a 2-year follow-up for all patients. The four twice-daily treatments were as follows: aspirin, 25 mg; extended-release dipyridamole, 200 mg; aspirin, 25 mg, plus extended-release dipyridamole, 200 mg; and placebo. A total of 6,602 patients were included in the analysis, and the outcome event clusters were fatal or nonfatal stroke, stroke or death from any cause, and all-cause mortality. The study showed that both extended-release dipyridamole (200 mg bid) and aspirin (25 mg bid) had an independent and statistically significant effect in reducing the risk of stroke recurrence (16% and 18%, respectively, when compared with placebo), and that the combination of extended-release dipyridamole plus aspirin was additive and produced highly significant benefits (37% risk reduction) for stroke prevention. Extended-release dipyridamole combined with aspirin reduced the risk of stroke (nonfatal and fatal) by 23% vs aspirin alone. The absolute risk reduction was 3% at 2 years, or about 1.5% annually. When the results of the ESPS-2 are added to those of the 14 previous trials of dipyridamole combined with aspirin vs aspirin alone in various atherosclerosis patients, there is a significant 23% reduction for dipyridamole plus aspirin compared with aspirin in the odds of nonfatal stroke and a nearly significant 10% reduction in the odds of all vascular events, though all of the 10% is attributable to nonfatal strokes.101
ESPS-2 was a cerebrovascular trial (ie, only patients with stroke or TIA were enrolled). When the results of ESPS-2 are added to those of the three previous cerebrovascular trials,102 103 104 105 there is a significant 25% reduction in the odds of nonfatal stroke for the combination of aspirin and dipyridamole vs aspirin alone and a significant 18% reduction in the odds of all vascular events, although again all of the 18% is attributable to nonfatal stroke.
Comparison of the Efficacy of Antiplatelet Agents: In summary, aspirin reduces the odds of the composite outcome of stroke, MI, or vascular death in all high-risk patients with symptomatic atherosclerosis by about 25%. It reduces the odds of stroke by about 30%. In trials limited to stroke/TIA patients, aspirin reduced the odds of the composite outcome of stroke, MI, or vascular death by only 16%. In stroke/TIA patients, ticlopidine reduces the same composite outcome by about a third, but there is a 5% incidence of bothersome adverse effects, a 0.9% incidence of severe neutropenia, and a small risk of TTP. The serious side effects of ticlopidine have led many experts to largely abandon its use. Clopidogrel produces a benefit similar to ticlopidine for the outcome cluster of stroke, MI, or vascular death, but may be less effective for prevention of stroke. The safety profile of clopidogrel is comparable to aspirin and safer than ticlopidine. Compared to placebo, dipyridamole in combination with aspirin reduces the risk of the composite outcome of stroke, MI, or vascular death in patients with symptomatic atherosclerosis by about 28%.81 In comparison with placebo, extended-release dipyridamole in combination with aspirin reduced the risk of stroke in patients with stroke/TIA by 37% in ESPS-2, which is nearly identical to the 38% stroke risk reduction that was obtained with the combination of dipyridamole and aspirin in a previous similar trial (ESPS-I).106 Although inadequately studied, the combination does not appear to provide benefit over aspirin alone for reducing MI.
Each of the alternative antiplatelet agents (ticlopidine, clopidogrel, and dipyridamole/aspirin) has been directly compared with aspirin in only one large study of cerebrovascular patients (Fig 6 ). The comparisons in Figure 6 of these three antiplatelet trials and agents are indirect and thus must be interpreted more cautiously than direct comparisons. The performance of antiplatelet agents in separate trials varies because patient populations and protocols differ, and unrecognized biases may exist. To our knowledge, no trials have performed direct comparisons between these alternative agents and physicians must make comparisons and clinical judgments based on the available data. Clearly, the relative benefit and safety of the various antiplatelet drugs, for various patients and vascular events, will remain uncertain unless very large trials directly comparing them are conducted.
|
Antiplatelet Agents for Secondary Prevention of Cardioembolic Stroke: In general, studies of antiplatelet agents for stroke prevention have focused on patients with TIAs or strokes of atherothrombotic (noncardioembolic) origin. Many of these studies specifically excluded patients with high-risk sources of cardiac embolism, such as atrial fibrillation. Only two large randomized studies have specifically evaluated the efficacy of antiplatelet agents for secondary prevention of cardiac embolism. The European Atrial Fibrillation Trial107 compared the efficacy of aspirin (300 mg/d) to placebo treatment in patients with atrial fibrillation who had suffered a stroke or TIA within the last 3 months. In this trial, aspirin was associated with a 16% reduction in the relative risk of stroke; however, this difference was not statistically significant. The Studio Italiano Fibrillazione Atriale study108 compared the efficacy of indobufen (a reversible inhibitor of cyclo-oxygenase) with warfarin (international normalized ratio [INR] 2.0 to 3.5) among 916 atrial fibrillation patients who had experienced a nondisabling stroke or TIA within the last 15 days. No significant difference in the incidence of stroke, MI, PE, or vascular death was noted between the two groups; however, the power of the study was not great enough to exclude a substantial difference between the efficacy of the two agents. Therefore, at present, only very limited data are available regarding the efficacy of antiplatelet agents for secondary prevention of cardioembolism. In general, oral anticoagulant therapy is the treatment of choice for secondary prevention of cardioembolic stroke (see below). For patients who have contraindications to anticoagulant therapy, antiplatelet agents are recommended.
2.2. Oral Anticoagulants
Primary and Secondary Prevention of Cardioembolic Stroke:
Oral
anticoagulant therapy is highly effective for both primary and
secondary prevention of stroke in patients with atrial fibrillation
(see chapter on antithrombotic therapy in atrial fibrillation). Atrial
fibrillation is the most common cause of cardiac embolism and is
responsible for about 50% of all cardiogenic emboli. In addition,
several other cardiac lesions can cause cardioembolic stroke. Other
high-risk sources of cardiogenic embolism include mitral stenosis,
mechanical prosthetic valves, recent MI, left ventricular mural
thrombus, atrial myxoma, dilated cardiomyopathies, infective
endocarditis, and marantic endocarditis (Table 2
).
|
T
